Evidence map›Paper›PMID 41535339›Full record

ArticleScientific reports2026

APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell.

Maria Rivera, Lucy Liu, Sabina Enlund, Chae-Eun Lim, Haoran Zhang, Kaifu Yang, Roman Sasik, Leslie A Crews, Kathleen M Fisch, Ramez N Eskander and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maria RiveraDivision of Regenerative Medicine, Department of Medicine, University of California, La Jolla, San Diego, CA, USA.
Lucy LiuDivision of Regenerative Medicine, Department of Medicine, University of California, La Jolla, San Diego, CA, USA.
Sabina EnlundDivision of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Chae-Eun LimDivision of Regenerative Medicine, Department of Medicine, University of California, La Jolla, San Diego, CA, USA.
Haoran ZhangDivision of Regenerative Medicine, Department of Medicine, University of California, La Jolla, San Diego, CA, USA.
Kaifu YangDivision of Regenerative Medicine, Department of Medicine, University of California, La Jolla, San Diego, CA, USA.
Roman SasikCenter for Computational Biology & Bioinformatics (CCBB), University of California, La Jolla, San Diego, CA, 92093-0681, USA.
Leslie A CrewsDivision of Regenerative Medicine, Department of Medicine, University of California, La Jolla, San Diego, CA, USA.
Kathleen M FischCenter for Computational Biology & Bioinformatics (CCBB), University of California, La Jolla, San Diego, CA, 92093-0681, USA.
Ramez N EskanderDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology & Reproductive Sciences, Moores Cancer Center, University of California, La Jolla, San Diego, CA, USA.
Frida HolmDepartment of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Qingfei JiangDivision of Regenerative Medicine, Department of Medicine, University of California, La Jolla, San Diego, CA, USA. q1jiang@health.ucsd.edu.

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
CTSA UM1 Program at University of California San Diego Altman Clinical and Translational Research InstituteUM1TR005449 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael A Hogarth, David Mitchell Smith · 2025 to 2026
$20.6M
Core transcriptional regulators of malignant stem cell generation in multiple myelomaR37CA252040 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Leslie A Crews · 2021 to 2026
$2.3M
Elucidate the Role of RNA Editing in Acute T-cell Lymphoblastic Leukemia Initiating CellsR01CA282792 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Qingfei Jiang · 2024 to 2026
$1.4M
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
FACSymphony S6 Cell Sorter for Improving Basic, Clinical, and Translational Cancer Research CapabilitiesS10OD032316 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SIGNER, ROBERT A.J. · 2022 to 2022
$600k
Profiling Epitranscriptomic RNA editing in Pediatric CancerR03CA287274 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JIANG, QINGFEI · 2024 to 2025
$316k
Examine the function of APOBEC3B in epithelial ovarian cancer stem cellsR03CA270853 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JIANG, QINGFEI · 2022 to 2023
$158k
NCATS NIH HHS UM1 TR005449NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA282792NCI NIH HHS R03 CA270853NCI NIH HHS R03 CA287274NCI NIH HHS R37 CA252040NIH HHS S10 OD026929NIH HHS S10 OD032316
6 · The paper itself

Abstract

Late detection and tumor recurrence are major factors driving the lethality of high-grade serous ovarian carcinoma (HGSOC). PARP inhibitors (PARPi) have achieved significant clinical efficacy by selectively targeting DNA repair deficiencies in HGSOC patients with BRCA mutations and homologous recombination deficiency (HRD). However, a subset of patients ultimately develops resistance to PARPi, necessitating alternative effective treatment options. The mutational signatures of APOBEC3 family of DNA deaminases are widespread across a broad array of cancer types. Here, we report that cancer stem cell (CSC)-like tumorspheres exhibit reduced A3B expression compared to non-CSC adherent counterparts. Importantly, inhibition of A3B leads to PARPi resistance, elevated frequency of CSCs, and enhanced expression of stemness factors. In addition, we found that high A3B-expressing cells are under strong replication stress and thus synergize efficiently with PARPi. These studies reveal the important role A3B plays in regulating PARPi response.

Indexed as

Cytidine DeaminaseMinor Histocompatibility AntigensNeoplastic Stem CellsOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsCell Line, TumorDrug Resistance, NeoplasmFemaleHumansAPOBEC3B protein, humanCytidine DeaminaseMinor Histocompatibility AntigensPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID41535339
PMCPMC12881425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.